Braidwell LP Has $57.96 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Braidwell LP trimmed its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 33.9% during the second quarter, HoldingsChannel.com reports. The fund owned 594,562 shares of the company’s stock after selling 304,802 shares during the quarter. Dianthus Therapeutics makes up 2.2% of Braidwell LP’s portfolio, making the stock its 12th biggest position. Braidwell LP’s holdings in Dianthus Therapeutics were worth $57,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. ABS Investment Management LLC bought a new stake in Dianthus Therapeutics during the second quarter worth $194,960,000. PNC Financial Services Group Inc. increased its stake in shares of Dianthus Therapeutics by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after purchasing an additional 139 shares during the last quarter. First Horizon Corp bought a new position in shares of Dianthus Therapeutics in the 1st quarter valued at $32,000. Virtus Investment Advisers LLC raised its holdings in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after buying an additional 416 shares in the last quarter. Finally, EFG International AG acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth $49,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Down 0.4%

NASDAQ DNTH opened at $106.24 on Thursday. The firm has a market capitalization of $5.81 billion, a PE ratio of -25.60 and a beta of 1.24. The business’s 50-day moving average price is $104.65 and its two-hundred day moving average price is $88.52. Dianthus Therapeutics, Inc. has a 12 month low of $23.66 and a 12 month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DNTH has been the topic of several research analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $124.27.

Insider Buying and Selling at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 16,167 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the sale, the senior vice president directly owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This represents a 80.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the sale, the chief executive officer directly owned 65,292 shares in the company, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 260,554 shares of company stock worth $27,211,775. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.